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Abstract
Background:  As part of efforts to control Japanese encephalitis (JE), the World Health
Organization is producing a set of standards for JE surveillance, which require the identification of
patients with acute encephalitis syndrome (AES). This review aims to provide information to
determine what minimum annual incidence of AES should be reported to show that the surveillance
programme is active.
Methods: A total of 12,436 articles were retrieved from 3 databases; these were screened by title
search and duplicates removed to give 1,083 papers which were screened by abstract (or full paper
if no abstract available) to give 87 papers. These 87 were reviewed and 25 papers identified which
met the inclusion criteria.
Results: Case definitions and diagnostic criteria, aetiologies, study types and reliability varied
among the studies reviewed. Amongst prospective studies reviewed from Western industrialised
settings, the range of incidences of AES one can expect was 10.5–13.8 per 100,000 for children.
For adults only, the minimum incidence from the most robust prospective study from a Western
setting gave an incidence of 2.2 per 100,000. The incidence from the two prospective studies for
all age groups was 6.34 and 7.4 per 100,000 from a tropical and a Western setting, respectively.
However, both studies included arboviral encephalitis, which may have given higher rather than
given higher] incidence levels.
Conclusion:  In the most robust, prospective studies conducted in Western industrialised
countries, a minimum incidence of 10.5 per 100,000 AES cases was reported for children and 2.2
per 100,000 for adults. The minimum incidence for all ages was 6.34 per 100,000 from a tropical
setting. On this basis, for ease of use in protocols and for future WHO surveillance standards, a
minimum incidence of 10 per 100,000 AES cases is suggested as an appropriate target for studies
of children alone and 2 per 100,000 for adults and 6 per 100,000 for all age groups.
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Background
As part of the effort to control Japanese encephalitis (JE),
the World Health Organization (WHO) is producing a set
of standards for JE surveillance [1]. The surveillance con-
sists of identifying patients with acute encephalitis syn-
drome (AES), and then classifying the patients according
to the results of laboratory diagnostic tests. AES is defined
as the acute onset of fever and a change in mental status
(including symptoms such as confusion, disorientation,
coma, or inability to talk) and/or new onset of seizures
(excluding simple febrile seizures) in a person of any age
at any time of year. As with all surveillance standards, the
document includes performance targets that give an indi-
cation of the quality of the surveillance. The minimum
annual incidence of a disease syndrome that one would
expect to be reported provides a vital indication of
whether surveillance is active. For example in the polio
eradication surveillance standards, an annual rate of non-
polio acute flaccid paralysis cases of 1 per 100,000 chil-
dren is the minimum that should be reported to show that
surveillance is active [2]. A performance target for the min-
imum annual incidence of AES was not defined in the
field test version of the Japanese encephalitis surveillance
standards [1], pending further information about the
likely minimum incidence of AES.
This review provides information to answer the question:
What is the minimum annual incidence of AES that
should be reported per 100,000 population to show that
the surveillance programme is active? Although there are
no studies that specifically address the incidence of AES (a
broad syndromic definition that includes many patients
who do not have encephalitis [3]), there are studies look-
ing at the incidence of encephalitis in different settings.
The surveillance standards have been devised for JE con-
trol and it is envisaged that in JE endemic areas, the
number of cases will fall as the disease control pro-
grammes are further implemented. Thus in addition to
looking at the incidence of JE in areas currently or histor-
ically endemic for JE we examined the incidence of AES in
Western industrialised areas where JE does not occur.
Results
A total of 12,436 articles were retrieved from 3 databases;
these were screened by title search and duplicates
removed to give 1,083 papers which were screened by
abstract (or full paper if no abstract available) to give 87
papers (Table 1). These 87 were reviewed and 25 papers
identified which met the inclusion criteria. All relevant
studies for producing the recommended incidence to be
used in the WHO surveillance standards included are
described below. Initially, 87 articles were considered [see
Additional file 1] and 25 articles were finally chosen
because they met the selection criteria and were represent-
ative of the spectrum of study type and disease incidence
(Tables 2 and 3). Studies were evaluated and reviewed to
Table 1: Literature search strategy and results.
Search Search Strategy Dates of 
original search
Numbers of 
articles (No limits)
Title screened 
articles
Totals from 
title screen
Duplicates 
removed
Further Title & 
Abstract or 
paper screen
1 Pubmed "Incidence or 
epidemiology" AND 
"encephalitis".
1950-autumn 
2007
6895 479 1083 87
2 Pubmed "encephalitis and 
epidemiology" AND" 
Japanese encephalitis 
Virus and Incidence"
1950-autumn 
2007
492 66 (-34 
duplicates) = 
32
527
3 Pubmed "encephalitis and 
epidemiology" AND 
"herpes and Incidence"
1950-autumn 
2007
266 43(-27 
duplicates) = 
16
4 OVID "Incidence or 
epidemiology" AND 
"encephalitis".
1950-autumn 
2007
Exploding each 
term 509 1467 – 
48 duplicates = 
1419
445 445
5 EMBASE "Incidence or 
epidemiology" AND 
"encephalitis". [Limits 
English, Human]
1966-autumn 
2007
1631 exploded 
terms 3369 – 
duplicates 3364
300 300
Totals 12,436 1,272 1,272 1,083 87Virology Journal 2008, 5:134 http://www.virologyj.com/content/5/1/134
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Table 2: Aetiology and outcome for each of the selected AES studies*
Study (Publication Year) Study Year Ages Aetiology confirmed Fatality Rate% Sequelae %
Klemola et al. (1965)[5], Kaeaeriaeinen et 
al. (1964)[6]
1945–1963 All ages 40% from 1958 onwards 10 33
Beghi et al. (1984)[4] 1950–1981 All ages 15.3 3.8 not reported
Henrich et al. (2003).[35] 1993–1998 All ages not reported not reported not reported
Pedersen (1956)[37] 1952–54 All ages not reported not reported not reported
Nicolosi(1986)[36] 1950–1981 All ages 15 3.8 not reported
Ponka et al. (1982)[13] 1980 All ages not reported not reported not reported
Khetsuriani et al. (2002)[18] 1988–1997 All ages 40.5 7.4 not reported
Khetsuriani et al. (2007)[34] 1988–1997 All ages 81.5 100 not applicable
Kamei et al. (2000)[17] 1989–1991 All ages 48.8 not reported not reported
Davison et al. (2003)[20] 1989–1998 All ages 40.1 9.7 56 (mild deficits)
Trevejo (2004)[19] 1990–1999 All ages 43.7 not reported not reported
Mailles, et al. (2007)[21] 2000–2002 All ages 16.8 15–28 not reported
Rantalaiho et al. (2001)[7] 1967–1991 >= 15 yrs 50.6 5.6 not reported
Radhakrishnan et al. (1987)[38] 1983–1984 >15 yrs 0 20 not reported
Nwosu et al.(2001)[33] 1991–1993 >= 16 yrs 0 50 0
Kupila et al. (2006)[9] 1999–2003 >= 16 yrs 35.7 not reported 71 (mild-severe deficits)
Koskiniemi et al. (1991) [8] 1968–1987 1 mths-16 yrs 68 3 7 severely damaged
Rantakallio et al. (1986)[39] 1966–1972 <14 yrs 38.1 not reported not reported
Koskiniemi et al. (1997)[11] 1983–1984 1 mths-15 yrs 62.9 not reported not reported
Ilias et al. (2006)[14] 2000–2004 <14 yrs 72.2 0 not reported
Wang et al. (1981)[40] 1972–1980 <=16 yrs 36 of all viral CNS infections not reported not reported
Rantala & Uhari (1989)[12] 1973–1987 <16 yrs 61.1 1.1 not reported
Wong et al. (1987)[41] 1975–1986 <14 yrs 26 28 24
Cizman et al. (1993)[15] 1979–1991 1mths-15 yrs 68.2 1.8 24 (neurological deficits)
Ishikawaet al. (1993)[16] 1984–1990 <15 yrs 41 7.8 66 (neurological deficits)
*Studies covering all ages are listed first, followed by adult studies and then paediatric studies. Within each section the studies are ordered by type; 
longitudinal (L), then prospective (P) and then retrospective (R) studies. Yrs Years, Mths Months.V
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Table 3: Summary of AES incidence rates in the selected studies
Study 
(Publication Year)
Year of Study Setting Country Western 
(W)/Tropical (T)
Study Design Longitudinal (L) 
Prospective (P)/Retrospective 
(R)/
Ages Incidence per 100,000 
population
Klemola et al (1965), 
Kaeaeriaeinen et al(1964)[5,6]
1945–1963 Finland (W) L All ages 2 to 3
Beghi et al. (1984)[4] 1950–1981 USA (W) P All ages 7.4
Henrich et al. (2003)[35] 1993–1998 Thailand (T) P All ages 6.34
Pedersen (1956)[37] 1952–54 Jutland (W) R All ages 6.75–9.25**
Nicolosi (1986)[36] 1950–1981 USA (W) R All ages 7.4
Ponka et al. (1982)[13] 1980 Finland (W) R All ages 3.5
Khetsuriani et al. 2002)[18] 1988 – 1997 USA (W) R All ages 7.3
Khetsuriani et al. (2007)[34] 1988–1997 USA (W) R All ages 0.51–0.53*(deaths)
Kamei et al. (2000)[17] 1989–1991 Japan (T) R All ages 1.77 *(± 0.32)
Davison et al. (2003)[20] 1989–1998 England (W) R All ages 
(children <17 yrs)
1.5 (2.8 in children) (1.1 in 
adults)
Trevejo (2004)[19] 1990–1999 USA (W) R All ages 4.3 (CI 4.2–4.4)
Mailles et al. 2007)[21] 2000–2002 France (W) R All ages 1.9
Rantalaiho et al. (2001)[7] 1967–1991 Finland (W) L Adults ≥ 15 yrs 1.4V
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Radhakrishnan et al. (1987)[38] 1983–1984 Libya (T) P Adults >15 yrs 1
Nwosu et al. (2001)[33] 1991–1993 Nigeria (T) P Adults ≥ 16 yrs 0.9
Kupila et al. (2006)[9] 1999–2003 Finland (W) P Adults ≥ 16 yrs 2.2
Koskiniemi et al. (1991)[8,10] 1968–1987 Finland (W) L Children 1 mths-6 yrs 8.3 (range 19.8 in 1974 to 2.5 
in 1986 and 1987)
Rantakallio et al. (1986) 1966–1972 Finland (W) P Children <14 yrs (1966 birth 
cohort)
12.6
Koskiniemi et al. (1997)[11] 1993–1994 Finland (W) P Children 1 mths-15 yrs 10.5
Ilias et al. (2006)[14] 2000–2004 Greece (W) P Children <14 yrs 13.8**
Wang et al. (1981)[40] 1972–1980 Canada (W) R Children ≤ 16 yrs 8.2**
Rantala & Uhari (1989)[12] 1973–1987 Finland (W) R Children <16 yrs 8.8
Wong et al. (1987)[41] 1975–1986 Hong Kong (T) R Children <14 yrs 14.25**
Cizman et al. (1993)[15] 1979–1991 Slovenia (W) R Children 1 mths-15 yrs 6.7 (range 2.37–12.6)
Ishikawa et al. (1993)[16] 1984–1990 Japan (T) R Children <15 yrs 3.3
* Incidence converted to/100,000, ** incidence calculated from data in paper. Yrs Years. Mths Months, P prospective, R retrospective, L Longitudinal, CI confidence interval. Studies covering all 
ages are listed first followed by adult studies and then paediatric studies. Within each section the studies are ordered by type; longitudinal, then prospective and then retrospective studies.
Table 3: Summary of AES incidence rates in the selected studies (Continued)Virology Journal 2008, 5:134 http://www.virologyj.com/content/5/1/134
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determine the incidence of AES, specific infectious aetiol-
ogies of encephalitis in various age groups and geographic
areas, and case definitions employed.
For the purpose of this paper, articles assessing AES were
categorised into Western industrialised and tropical set-
tings, where Western countries were defined as belonging
to Europe and North America. Nineteen articles discussed
AES in Western industrialised countries and the remain-
ing 6 looked at AES in Tropical countries (Tables 2 and 3)
and [see Additional file 1]. For the 62 additional papers
from Western countries where specific disease incidences
were given, viral agents included St Louis encephalitis
virus (SLEV), tick-borne encephalitis virus (TBEV), herpes
simplex virus-1 and 2 (HSV-1 &2), measles virus, West
Nile virus (WNV) and varicella zoster virus (VZV) [see
Additional file 1]. These studies illustrate that arboviruses
are also important causes of encephalitis in Western set-
tings but there is a greater range of viruses reported than
in tropical settings, many of which like JE are vaccine pre-
ventable. From tropical countries Japanese encephalitis
virus (JEV) studies predominated.
Incidence of encephalitis of any cause
Of the 25 studies that met the selection criteria, fourteen
are discussed here in more detail as they include the stud-
ies from which the incidences for surveillance data are
suggested, as well as examples of other similar studies
from Western and tropical settings. More information is
available from these and all 87 papers [see Additional file
1].
In a prospective population-based study, all cases fulfill-
ing a case definition for encephalitis were identified for
the period 1950–1981, in Olmsted County, Minnesota,
USA [4]. Cases considered as 'possible' were excluded
from all calculations, even though age distribution, sea-
sonal trends and residence were similar to 'confirmed'
cases. Although all causes were studied, mumps virus and
the California serogroup viruses were the most commonly
identified causes and by the last decade of the study, the
rate at which a viral aetiology was determined had
improved to approximately 25%. The overall annual inci-
dence of 7.4 per 100,000 remained stable over successive
5 to 10 year periods. The case fatality rate was 3.8%.
There have been a large number of studies of encephalitis
from Finland, the earliest of these is a longitudinal study
from 1945–1963 [5,6] in which patients of all ages with
an acute infectious disease of apparent viral aetiology
were studied. Virological diagnostics changed over the
course of the study and viral isolation was introduced as
routine in 1952. In this study the overall incidence of viral
encephalitis was found to be 2 to 3 per 100,000.
A more recent longitudinal hospital-based study covering
the period 1967 to 1991 aimed to provide good surveil-
lance coverage of acute encephalitis over a large part of
Southern Finland [7]. Of 322 adult patients, aetiology was
confirmed, probable or suggested in 51%, with HSV being
the most frequent causative agent. Employing stringent
exclusion, case definition and laboratory diagnostic crite-
ria, an annual incidence of 1.4 per 100,000 was reported.
Mumps virus was the leading cause of acute encephalitis
until effective vaccination programmes virtually elimi-
nated it from Finland [8].
Patients aged 16 or over admitted to one main hospital in
Finland between 1999 and 2003 were included in a study
investigating encephalitis and aseptic meningitis [9]. This
prospective study provided detailed case and laboratory
diagnostic criteria and aimed to investigate the effective-
ness of polymerase chain reaction (PCR) in the diagnosis
of encephalitis. Aetiology was defined in 36% of patients
after microbiological testing, with VZV, HSV and TBEV the
major causative agents. An annual incidence of 2.2 per
100,000 encephalitis cases was reported.
A study of 462 children with encephalitis, aged 1 month
to 16 years was conducted between 1968 and 1987 in Hel-
sinki, Finland and hospital admission data for the 462
children were collated [8]. The average incidence of
encephalitis was 8.8 per 100,000 (range 19.8 in 1974 to
2.5 in 1985 and 1986). Further data from this cohort
showed that highest incidence of encephalitis was in chil-
dren under 1 year of age (annual incidence 16.7 per
100,000); the incidence remained quite high until 10
years of age, and then gradually declined for children up
to the age of 15 years (annual incidence 1.0 per 100,000)
[10]. Since 1983, when measles, mumps and rubella
(MMR) vaccine was introduced, the major associated
agents were Mycoplasma pneumoniae, enteroviruses and
adenoviruses. Morbidity and mortality rates were not
specified.
A prospective multicentre study in Finland identified 175
cases of acute encephalitis in children aged 1 month to 15
years, and reported an overall annual incidence of 10.5
per 100,000 [11]. Again, the highest annual incidence
occurred in the youngest children (18.4 per 100,000 in
children under 1 year of age). In this later study, which
followed the virtual elimination of encephalitis due to
measles, mumps or rubella viruses, the microbial diagno-
sis was proven or suggested in 110 cases (63%), with VZV,
respiratory or enteroviruses comprising 61% of these, and
adenovirus, Epstein Barr virus, HSV and rotaviruses com-
prising another 5% each.
A retrospective population-based study of children with
encephalitis was conducted between 1973 and 1987 in anVirology Journal 2008, 5:134 http://www.virologyj.com/content/5/1/134
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area of Finland where there were no arboviral infections
[12]. Ninety-five children were identified, giving an
annual incidence of 8.8 per 100,000. The most commonly
identified agents, based on virological and serological
studies were VZV (24 cases), mumps virus (8), HSV (7)
and measles virus (4). The aetiology remained unknown
in 37 children (39%). No cases of encephalitis caused by
mumps virus, measles virus or rubella virus were found in
the population after 1982, when the MMR vaccine against
these viruses was introduced. This was also noted by other
researchers in Finland [8].
In a small prospective study of central nervous system
(CNS) infections in Helsinki, Finland in 1980, 146
patients were diagnosed with CNS infections with a cere-
brospinal fluid (CSF) pleocytosis (>10 cells/mm3), of
whom 9 had meningo-encephalitis or encephalitis. This
prospective data together with retrospectively collected
data for the same period from other hospitals in Helsinki
gave an incidence hospitals in of 3.5 per 100,000 [13].
A retrospective study performed in Heraklion, Crete from
2000 to 2004, identified 18 children hospitalised for
acute encephalitis, giving an incidence rate of 13.8 per
100,000 [14]. Aetiology was attributed to viral causes in 8
cases, bacterial in a further 5 and a remaining 5 cases were
of unknown cause. The absence of measles, mumps or
rubella virus associated encephalitis cases was interpreted
by the authors to be consistent with the elimination of
these encephalitides in the post vaccine era. Although no
fatalities occurred, 5 children presented at a median of 4
years after their initial infection with mild to moderate
sequelae.
In Slovenia, a retrospective study covering a 13 year
period from 1979 to 1991 identified 170 children (aged 1
month to 15 years) with encephalitis, giving an incidence
of 6.7 per 100,000 [15]. A definite or probable aetiology
was determined in 68% of cases, with TBEV (28.8%), VZV
(17.0%), HSV (10.0%) being the most common agents. A
subgroup of 42 children with encephalitis and focal neu-
rological signs was identified, among whom the most
common confirmed or presumed infective agent was HSV
(40.4%).
A questionnaire-based epidemiological study in Japan
covering a 7-year period from 1984 to 1990 identified 256
patients with acute encephalitis [16]. The authors esti-
mated an overall annual incidence of encephalitis of 1.77
(+/-3.2) per 100,000 in children [17]. Among 105 aetio-
logically diagnosed cases, the most common causative
agents were measles virus (23%), rubella virus (23%) and
HSV (20%). The short term outcome was death in 20
cases and varying degrees of neurological sequelae includ-
ing subsequent epilepsy, visual and auditory deficits and
mental/physical impairment in a further 24%.
An analysis of United States National Hospital Discharge
Survey data from the period 1988 to 1997 revealed an
average encephalitis-associated hospitalisation rate of 7.3
per 100,000 [18]. Herpetic and toxoplasmic encepha-
litides were the most common individual diagnoses with
known agents. Encephalitis-associated hospitalisation
rates were highest for children less than 1 year of age and
persons aged 65 years or over. A fatality rate of 7.4% was
reported. Another analysis of US hospital discharge data
for the period 1990 to 1999 reported an overall incidence
rate of 4.3 per 100,000 for encephalitis admissions in Cal-
ifornia [19]. Once again the highest rate was found in
infants aged less than 1 year.
In a retrospective analysis of hospitalisations for a diagno-
sis of viral encephalitis in England between 1989 and
1998, 6414 cases were identified [20]. Most cases (60%)
were of unknown aetiology, but HSV was the most fre-
quent causative agent among cases with an identified
cause, accounting for 52%. An overall annual incidence
rate of 1.5 per 100,000 was reported. The highest rate (8.7
per 100,000) was for children under 1 year of age. The
overall case-fatality rate was 6.5%. Significant under-
reporting of viral encephalitis was noted when routine
systems were compared to the hospital episode statistics,
with 97% of hospitalised cases not being formally
reported.
Most recently, a retrospective French population-based
study undertaken between 2000 and 2002, using the
national hospital medical database, found an annual
average incidence of acute encephalitis of 1.9 per 100,000
[21]. Aetiological diagnosis was not made in 80% of cases,
but HSV and VZV were the most common identified
causes. Comparison with other studies was hampered by
the exclusion of patients infected with HIV. The fatality
rate was 6% and by 6 months, 71% patients experienced
moderate to severe sequelae.
Incidence of Japanese encephalitis
Many studies set in Western industrialised countries tend
to focus on HSV, TBEV, SLEV, WNV or bacterial encepha-
litides [see Additional file 1]. In contrast, tropical coun-
tries are faced with high incidences of JE and so the
majority of studies arising from Southeast Asia, Japan and
China, for example, are focused on the epidemiology of
JE.
Tigertt et al. (1957) conducted a programme in Japan over
a 4-year period before 1950 aiming to investigate the effi-
cacy of a formalin-inactivated mouse-brain vaccine in an
area where JE was relatively common [22]. ChildrenVirology Journal 2008, 5:134 http://www.virologyj.com/content/5/1/134
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recruited from Okayama Prefecture in Japan were admin-
istered 3 doses of vaccine. Although no cases of AES were
reported to have occurred in 1946, in the subsequent 4
years there was an overall rate of 41.2 per 100,000 across
the region. However, a dramatically lower rate of 11.8 per
100,000 was observed in those vaccinated under the study
programme.
A prospective study set in Chiangmai Valley, Thailand in
1970 reported the annual incidence among residents of
the valley to be 14.7 per 100,000 [23]. The area had
known geographic boundaries and a population that
could be described demographically with reasonable
accuracy thus allowing the cases themselves to help
describe the temporal and spatial occurrence of JE. A sim-
ilarly high incidence has been reported for other epidemic
areas of Southeast Asia such as in Northern Vietnam
where between 1969 and 1974, incidence rates of 8.7 to
22.0 per 100,000 were reported [24].
Between 1968 and 1971 JE surveillance in Taiwan was
conducted with WHO-assisted programmes. Okuno et al.
(1975) found a clear pattern of JE consistently occurring
in mid July mostly in the southernmost county of Taiwan
[25,26]. The study population was that of Taiwan itself
and other offshore islands such as the Pescadores. After
patients were identified, blood and convalescent sera were
obtained, and of 1,024 patients, 273 were confirmed as
JE. An incidence of between 2 and 7 per 100,000 was
reported across the study period. Case fatality never
exceeded 25%.
Unlike the other studies carried out in tropical settings,
Hoke  et al. (1988) performed a placebo-controlled,
blinded randomised clinical trial in a northern Thai Prov-
ince between 1984 and 1985 to assess the efficacy of 2 dif-
ferent vaccines [27]. A cohort of children aged between 1
and 14 years was selected from 12 schools for the study. A
marked difference in incidence of JE was observed in the
non-vaccinated compared to the vaccinated groups; 51
per 100,000 compared to 5 per 100,000 respectively.
A wide range of incidence of JE in Thailand was noted dur-
ing the late 1980s, with the northern provinces particu-
larly affected with average incidences of 5 per 100,000
compared to other provinces with an average incidence of
2 per 100,000 (range 1.69–6.68 per 100,000). JE was
noted to be less common in southern and central areas
than in the north [28]. The majority of cases (85%) were
in those under 25 years of age and 66% of all cases
occurred in children less than 15 years of age, with the
highest rate in those aged 5 to 9 years. No specific detail
for case definition or laboratory diagnosis was provided,
although the overall conclusions of this study seem to
agree with other detailed studies set in the same location
[25,29]. The study highlights the importance of good epi-
demiological data to appropriately target JE control meas-
ures.
In Taiwan the incidence of JE is reported to have decreased
since the introduction of vaccination in 1968. This is evi-
dent from a prospective population-based study carried
out here over a 30-year period where the annual incidence
of 2.05 per 100,000 in 1967 dropped to 0.03 per 100,000
in 1997 [30]. This study excluded non-confirmed cases
and non-JE cases. The dramatic decrease in JE occurrence
was attributed to a combination of the improved living
conditions due to urbanisation, and use of insecticides
coupled with a lasting childhood immunisation cam-
paign. Although the mortality rate decreased in line with
incidence, 40% of all patients who survived JE developed
sequelae.
More recently in Bali, a prospective hospital-based surveil-
lance study of children younger than 12 years gave an inci-
dence of JE of 7.1 per 100,000 from a population of
approximately 600,000 where 86 confirmed and 4 proba-
ble cases were identified [31]. The incidence was notably
higher in the southern plains than in the mountainous
districts of northern Bali, and was attributed to a wider
distribution of rice fields in the south. Among survivors
37% had neurological sequelae at discharge and 10% of
the children died. In epidemic years the incidence of JE
can be much higher than these, with incidences as high as
185 reported from an outbreak in Nepal in 1997 [32].
These findings contradict suggestions that JE is rare in
tropical Asia and suggest the geographical range of JE is
broader than previously thought. Vaccination implemen-
tation is being considered in Bali.
Discussion
This review has shown a wide range of reported incidences
for acute encephalitis, both in tropical and Western indus-
trialised settings, ranging from 0.9 per 100,000 for adults
in Nigeria [33], to 185 per 100,000 for a rural population
during a JE outbreak in Nepal [32]. The key question we
set out to address was what is the minimum incidence of
acute encephalitis syndrome that should be reported to
show that there is active surveillance taking place? We
have found that in the most robust prospective studies
conducted in Western industrialised countries, a mini-
mum incidence of 10.5 per 100,000 AES cases was
reported for children and 2.2 per 100,000 for adults. A
minimum incidence rate of 6.34 per 100,000 was
reported for all ages from a tropical setting.
To reach this answer, we looked at the incidence of
encephalitis in a range of studies. Our analysis is hindered
to some extent by the very different methodologies used.
In addition it should be remembered that the number ofVirology Journal 2008, 5:134 http://www.virologyj.com/content/5/1/134
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patients with a final diagnosis of encephalitis is likely to
be considerably lower than the number that meet the
rather broad WHO case definition of acute encephalitis
syndrome on hospital admission (in essence any patient
with a febrile illness, altered consciousness and/or sei-
zures). For example, a recent assessment of the WHO JE
case definitions in Vietnam has shown that only 88 (30%)
of 296 patients with acute encephalitis syndrome had a
final diagnosis of encephalitis; the most common final
diagnoses were meningitis, other infectious encephalopa-
thies, and non-infectious causes [3].
Case definitions and diagnostic criteria
Of the 12 studies which looked at incidence of AES in all
age groups, 5 studies relied on WHO International Classi-
fication of Disease (ICD) codes (9th edition [18,19,34],
10th edition [21], or both [20]) in place of clinical case
definitions for cases of suspected acute encephalitis.
Although ICD codes used on discharge provide a useful
means of comparing data between hospitals [18] and
studies comparing different populations, they can hinder
precise aetiological diagnosis due to their generic nature.
Additionally, because the unit of analysis is a hospital dis-
charge and not a patient, multiple hospital admissions by
the same patient can lead to difficulties in determining the
true incidence rate in a given study [18]. One study
attempted to overcome this problem by recording the
record linkage number (relating to a patient's social secu-
rity number) wherever possible, to identify patients with
multiple hospitalisations [19].
Case definitions for encephalitis, where specified, varied
remarkably between studies and made comparisons diffi-
cult. Of the 25 studies of AES, apart from the 5 studies
relying on WHO ICD codes, 15 [4,5,7,13-17,35-41] gave
no detailed clinical case definition for an acute encephali-
tis case, including two studies in which diagnosis was at
the discretion of the consulting physician [16,37]. Con-
siderable variation was noted in case definitions
employed by the remaining 5 studies [9-12,33]. Use of
standardised case definitions will be important for the
reliability of data from future studies. Three studies failed
to provide exclusion criteria [13,20,35].
Aetiology confirmation
No laboratory diagnostic criteria were specified in 10
studies [5,16-18,33,34,37-40]. Most studies that specified
laboratory diagnostic criteria relied on a combination of
complement fixation and haemagglutination inhibition
in CSF and/or serum, using either single or paired speci-
mens from different phases of each patient's infection.
Evaluating antibody titres may be problematic however,
especially in young children as development of antibody,
particularly in CSF may occur late [11]. Serum antibodies
may indicate an associated infection rather than a causa-
tive CNS infection and could potentially lead to a falsely
high incidence rate if not taken into account.
Despite extensive microbiological investigation, there was
always a significant proportion of patients with no causa-
tive agent identified (28–85% unconfirmed). Two princi-
ple explanations for this might be firstly that the screening
techniques used were not adequate to detect all possible
causative agents, and secondly that a proportion of
encephalitides, such as those due to VZV, measles virus or
Mycoplasma pneumoniae, are post infectious and the causa-
tive agent might not be identifiable by the screening tests
employed. In addition not all encephalitis cases are
caused by microorganisms. The proportion of aetiologi-
cally confirmed acute encephalitis cases has varied in the
past from 15–100% [23,25,28,30]. The commonest iden-
tified cause was HSV, with a relatively consistent inci-
dence across the globe probably reflecting a lack of
geographical specificity for herpes viruses.
Reliance upon passive systems of encephalitis reporting
by healthcare providers and diagnostic laboratories may
lead to under-reporting, even where aetiology has been
confirmed [19,20]. Similarly, under-reporting may also
occur either because acute encephalitis is not a notifiable
disease, or as a result of variation in practice between
countries [9]. Regional variation within countries in the
proportion of hospitalisations where aetiology was con-
firmed also occurred, perhaps reflecting variation in clini-
cal and laboratory diagnostic practice [20]. For some
clinicians, confirmation of aetiology may not be seen as a
priority, especially if all suspected cases of acute encepha-
litis are routinely treated with acyclovir [20].
Accurate aetiological diagnosis is required to increase the
usefulness of surveillance of acute encephalitis, especially
in view of concerns about new and re-emerging infections
[7,19,42].
Study type and reliability
Of the 25 studies reviewed, only 12 covered all ages. Of
these, 1 was longitudinal observational [5], 2 were pro-
spective [4,35]. Of these 2 were from Western settings and
one from Thailand [35]. Of the 12 studies covering all
ages, 5 were population-based [18,20,21,34,35], 5 were
hospital surveillance, admission, or discharge-based
[4,5,13,19,36] and 2 analysed the response from a uni-
form questionnaire sent to all relevant institutions within
the study population [17,37]. Although prospective,
observational or interventional study design is optimal,
the majority of the studies reviewed could not be con-
ducted in this way for logistical reasons. An advantage of
using hospital discharge data is that most patients with
encephalitis were likely to be hospitalised because of the
severity of the illness [19]. However some patients mayVirology Journal 2008, 5:134 http://www.virologyj.com/content/5/1/134
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die before reaching the hospital, thus not being included.
Population-based studies in the past have not provided
good estimates of the overall disease burden of acute
encephalitis because they either focused on specific path-
ogens or were conducted in small populations [36,43].
Retrospective studies [15,18] can only review cases that
have been confirmed as acute encephalitis of any cause,
within a specified time-limit and so analyses will always
be dependent on the quality of record keeping during the
study period, clinical case definitions applied and labora-
tory criteria employed at the time of diagnosis. Recall bias
and small sample sizes may have also significantly ham-
pered these retrospective studies [15,18] including the
possibility of an over or under estimation of acute
encephalitis incidence.
Vaccination
The epidemiology of acute encephalitis has changed sub-
stantially over the years with the introduction of vaccines.
In particular, a dramatic change in the aetiology of child-
hood encephalitis in Finland has been observed since vac-
cination programmes eradicated measles-, mumps- and
rubella-associated encephalitides [44]. Similar effects
have been reported in other studies based in the West
[12,36] and in the tropics where JE vaccinations have been
used [25].
Incidence rates of acute encephalitis in Western 
Industrialised countries
Most of the studies of acute encephalitis of any cause have
emerged from Western countries, where HSV, measles,
mumps or rubella viruses were the most commonly iden-
tified causative agent. HSV has been known to be an
important cause of encephalitis for some time [45]. Its
rapid identification and effective treatment is crucial, par-
ticularly amongst middle-aged and elderly people who
appear most vulnerable to its sequelae [46]. Of concern
are reports of an increase in arthropod-borne viruses in
Western countries [8,18]. WNV outbreaks in North Amer-
ica, Southern Europe, Africa and Asia [47] have drawn
attention to the potential for spread of mosquito-borne
viruses [42,48].
The 19 studies set in the West have a range of annual inci-
dence from 1.4–13.8 per 100,000. Children only were
studied in 9 reports [10-12,14-16,39-41,49], 4 studied
adults only [7,9,33,38], and 12 studied all ages
[4,5,13,17-21,34-37]. One study gave incidence figures
for both adult and paediatric populations [20]. One study
reported encephalitis mortality only [34]. In the prospec-
tive study from a Western setting looking at all age groups,
which included arboviral infections, the incidence of
encephalitis was 7.4 [4].
In the paediatric studies the incidence of encephalitis
ranged from 2.37 to 14.25 per 100,000 overall, changing
to 10.5 to 13.8 per 100,000 if only the 2 prospective stud-
ies are included [11,14], giving a minimum incidence of
10.5 per 100,000 [12]. Both of these studies were from
Western countries.
In the adult studies, the lowest reported incidences were
0.9 [33],1 [38],1.4 [7], and 2.2 [9] per 100,000. All of
these were single-centre hospital-based prospective stud-
ies with relatively small sample sizes. In the 12 studies
including all age groups the incidence per 100,000 ranged
from 1.5 to 9.25 [4,5,13,18-21,34-37]. The two studies
from a Western setting of all age groups, with incidences
of less than 2.0 per 100,000 were both retrospective anal-
yses of national hospital episode statistics or medical
databases from England and France [20,21]. Given that
these are dependent on the discharge coding diagnoses,
which are notoriously unreliable, it is perhaps not surpris-
ing that they gave a lower incidence than the prospective
hospital-based studies.
The two studies in adults with incidences of 1.0 or less per
100,000 were both prospective studies from a tropical set-
ting, one from Libya and one from Nigeria. Both studies
included all CNS infections and then subdivided them by
diagnosis. In the discussion for both studies the authors
are careful to explain the lack of viral diagnostic facilities
and cite this as a possible reason for the relatively low inci-
dence of encephalitis in their studies [33,38]. Whilst this
is a valid concern, their findings should not be dismissed.
Even in the case of JE where incidences can reach 389 per
100,000 during outbreak situations [50] the reported inci-
dence can be as low as 0.4 per 100,000, in JE endemic
areas where vaccination has not occurred, if the diagnostic
capabilities are limited [51].
Incidence of Encephalitis in Tropical Countries
In recent years, the epidemiology and distribution of JE
has changed [52]. The disease incidence is decreasing in
China, Japan and Korea, and Thailand where it appears to
be associated with widespread vaccination campaigns; in
contrast it appears to be increasing in parts of Bangladesh,
Burma, India, Nepal, and Vietnam [16,23,25,31,53,54].
Although the reasons for these changes are not clear, they
may include the adoption of rice cultivation, establish-
ment of larger pig farms and promotion of pig-breeding as
a food source, and possibly climate changes [52]. Data
from tropical countries successfully implementing vacci-
nation, would suggest that even where JE incidence has
fallen as a result, the minimum overall incidence of viral
acute encephalitis in JE endemic areas is similar to that in
Western industrialised countries [26,27,31], with the
reported incidence of JE in the tropics ranging from 2 to
15 per 100,000.Virology Journal 2008, 5:134 http://www.virologyj.com/content/5/1/134
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Conclusion
From the 25 studies reviewed in detail, in the most robust,
prospective studies conducted in Western industrialised
and tropical countries a minimum incidence of 10.5 per
100,000 AES cases is reported for children and 2.2 per
100,000 for adults and 6.34 per 100,000 for all ages. For
ease of use in protocols and as benchmarks we therefore
suggest that the 2 per 100,000 be used as the minimum
incidence for adults, and 10 per 100,000 for children and
6 per 100,000 for all age groups for use in future WHO
AES surveillance standards.
The fact that the aetiology of acute encephalitis remains
unknown in the majority of patients [15] represents a
diagnostic challenge for the future. The increasing inci-
dence of encephalitis due to emerging agents, such as JEV,
WNV [19], TBEV [15], and Mycoplasma pneumoniae [49],
will present additional challenges. This review shows that
in most studies conducted in both Western industrialised
and tropical countries, an overall incidence of acute
encephalitis of between 1 and 15 per 100,000 is reported,
with higher incidences in children than adults. There were
no prospective studies from tropical settings looking at
the incidence of acute encephalitis in children only.
Methods
A series of literature searches were performed using three
search engines (PubMed, OVID and EMBASE) to identify
epidemiological studies that estimate the incidence of AES
in Western industrialised and tropical countries (Table 1).
The search results for each database were assessed for
duplicate articles. Studies were considered further if they
(1) performed population-based surveillance for
encephalitis cases, AES, or specific infectious aetiologies
of encephalitis in a well-defined geographic area and time
frame, or (2) performed sentinel or hospital-based sur-
veillance for the above diagnoses or syndrome in a geo-
graphic area and time frame for which the population
could be estimated and an incidence calculated. The
abstracts of acceptable articles were read and those that
matched our criteria were analysed further. Additionally,
articles already known to the authors, or cited by articles
identified during the above literature search, were also
retrieved, assessed and included if appropriate.
In summary, 7,653 articles were retrieved from Pubmed,
1,419 were retrieved from OVID and 3,364 were retrieved
from EMBASE using the above search criteria. This
totalled 12,436 articles at the time the search was carried
out in June to August 2008. In view of the large number of
retrieved articles, the authors carried out an initial screen-
ing by title to select only the articles most applicable to
our inclusion criteria and to remove duplicates. Abstracts
of 1,083 articles with relevant titles were reviewed further
together with other articles already known to the authors
and matching the inclusion criteria or referenced by other
articles from the database search. Of these, 87 articles were
considered relevant. These, were read through fully. 25
articles exactly matching our criteria were thus included
for study with an additional 62 included as they gave val-
ues for incidences of viral encephalitis due to specific
viruses. Papers in which incidence data were not given but
where there was sufficient data given in the paper for the
values to be calculated were also included. All incidence
figures are presented as incidence per 100,000 population
for ease of comparison between them. Articles were
excluded throughout for a number of reasons; some did
not discuss encephalitis despite being retrieved through
the 'encephalitis' keyword. Others discussed laboratory
markers rather than incidence in a given population;
including several articles claiming to discuss encephalitis
epidemiology, which despite providing good details on
their study design, lacked actual incidence figures.
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